Completed PHASE4 INTERVENTIONAL 1-arm NCT02316327

Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and Bevacizumab

Phase IV/II Open-label Study to Evaluate Prompt Response to Treatment With Cisplatin, Gemcitabine and Bevacizumab in Patients With Non-small Lung Cancer.

Sponsor: Fundacion Clinic per a la Recerca Biomédica

Conditions Non-Small Cell Lung Cancer (NSCLC)

Interventions gemcitabine, cisplatin and bevacizumab

Updated 5 times since 2017 Last updated: Oct 4, 2016 Started: Jul 31, 2013 Primary completion: Sep 30, 2016 Completion: Oct 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Non-Small Cell Lung Cancer (NSCLC) and is currently completed. Fundacion Clinic per a la Recerca Biomédica leads this study, which shows 5 recorded versions since 2013 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jul 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fundacion Clinic per a la Recerca Biomédica

Data source: Fundacion Clinic per a la Recerca Biomédica

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Barcelona, Spain